Cat. No.: HY-100573A

(E/Z)-Necrosulfonamide

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

(E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

For research use only. We do not sell to patients.

Purity: 98.03%
CAS No.: 432531-71-0
Formula: C₁₈H₁₅N₅O₆S₂
Molecular Weight:461.47

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

(E/Z)-Necrosulfonamide Chemical Structure

CAS No.: 432531-71-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Caspase Isoforms :

All NOD-like Receptor (NLR) Isoforms :

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

All NO Synthase Isoforms :

All Heme Oxygenase (HO) Isoforms :

HO-1
HO-2

Cellular Effect

Cell Line	Type	Value	Description	References
HT-29	IC₅₀	<200 nM Compound: 66; NSA	Anti-neprotic activity in human HT-29 cells assessed as reduction in TSZ-induced necroptosis incubated for 24 hrs by cell titer glo-based luminescence assay Anti-neprotic activity in human HT-29 cells assessed as reduction in TSZ-induced necroptosis incubated for 24 hrs by cell titer glo-based luminescence assay	[PMID: 31622096]
HT-29	IC₅₀	<1 μM Compound: 34; NSA	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay	[PMID: 36781172]
HT-29	IC₅₀	124 nM Compound: 34; NSA	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay	[PMID: 36781172]
Jurkat	IC₅₀	<1 μM Compound: 34; NSA	Anti-necroptotic activity in FADD null human Jurkat cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay Anti-necroptotic activity in FADD null human Jurkat cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay	[PMID: 36781172]

Chemical Information

CAS No. 432531-71-0
Appearance Solid
Molecular Weight 461.47
Formula C₁₈H₁₅N₅O₆S₂
Color Light yellow to yellow
SMILES

O=C(/C=C/C1=CC=C(S1)[N+]([O-])=O)NC2=CC=C(C=C2)S(=O)(NC3=NC=CN=C3OC)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All IF

Sort by:

Journal Impact Factor

J Cell Mol Med

New mechanism of nerve injury in Alzheimer's disease: β-amyloid-induced neuronal pyroptosis. [Abstract]

2020 Jul;24(14):8078-8090. PMID: 32521573

(E/Z)-Necrosulfonamide purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2020 Jul;24(14):8078-8090. [Abstract]

Results of PI and Hoechst 33 258 staining: Aβ1‐42 intervention increases the number of positive‐staining cells, while NSA intervention significantly decreases the number of positive-staining cells, and NSA could attenuated the opening degree of membrane pores.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (216.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1670 mL

10.8349 mL

21.6699 mL

5 mM

0.4334 mL

2.1670 mL

4.3340 mL

10 mM

0.2167 mL

1.0835 mL

2.1670 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]

[2]. Sun L, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1-2):213-227. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1670 mL	10.8349 mL	21.6699 mL	54.1747 mL
	5 mM	0.4334 mL	2.1670 mL	4.3340 mL	10.8349 mL
	10 mM	0.2167 mL	1.0835 mL	2.1670 mL	5.4175 mL
	15 mM	0.1445 mL	0.7223 mL	1.4447 mL	3.6116 mL
	20 mM	0.1083 mL	0.5417 mL	1.0835 mL	2.7087 mL
	25 mM	0.0867 mL	0.4334 mL	0.8668 mL	2.1670 mL
	30 mM	0.0722 mL	0.3612 mL	0.7223 mL	1.8058 mL
	40 mM	0.0542 mL	0.2709 mL	0.5417 mL	1.3544 mL
	50 mM	0.0433 mL	0.2167 mL	0.4334 mL	1.0835 mL
	60 mM	0.0361 mL	0.1806 mL	0.3612 mL	0.9029 mL
	80 mM	0.0271 mL	0.1354 mL	0.2709 mL	0.6772 mL
	100 mM	0.0217 mL	0.1083 mL	0.2167 mL	0.5417 mL

Keywords

(E/Z)-Necrosulfonamide

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

(E/Z)-Necrosulfonamide

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Neuroprotective Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Covalent Screening Library Plus

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Pattern Recognition Receptors Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) (E/Z)-Necrosulfonamide

All Caspase Isoforms

All NOD-like Receptor (NLR) Isoforms

All TNF Receptor Isoforms

All Interleukin Related Isoforms

All NO Synthase Isoforms

All Heme Oxygenase (HO) Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

(E/Z)-Necrosulfonamide Related Classifications

HY-100573A Related Classifications